Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Various groups including animal protection organizations, medical organizations, research centers, and even federal agencies such as the U.S. Food and Drug Administration, are working to minimize animal use in scientific experiments. This movement primarily stems from animal welfare and ethical concerns. However, recent advances in technology and new studies in medicine have contributed to an increase in animal experiments throughout the years. With the rapid increase in animal testing, concerns arise including ethical issues, high cost, complex procedures, and potential inaccuracies. Alternative solutions have recently been investigated to address the problems of animal testing. Some of these technologies are related to stem cell technologies, such as organ-on-a-chip, organoids, and induced pluripotent stem cell models. The aim of the review is to focus on stem cell related methodologies, such as organoids, that can serve as an alternative to animal testing and discuss its advantages and limitations, alongside regulatory considerations. Although stem cell related methodologies has shortcomings, it has potential to replace animal testing. Achieving this requires further research on stem cells, with potential societal and technological benefits. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · Nephron · doi:10.1159/000433566 · Cited by 3,515
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196 · cited 2×
“This may result in only partial replication, leading to an incomplete disease model [ 38].”
BackgroundVascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 1×
“Another study focused on the use of liver hepatoblasts, which could help alleviate hepatotoxicity through liver development and hepatic differentiation [ 85].”
BackgroundWhy 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
Huch, M., Dorrell, C., Boj, S. F., van Es, J. H., Li, V. S. W., van de Wetering, M., Sato, T., Hamer, K., Sasaki, N., Finegold, M. J., et al. (2013) · Nature · doi:10.1038/nature11826 · Cited by 1,555 · cited 1×
“There are also more direct methods like implantation to test the in vivo functions of organoids [ 65, 70 ] (Table 3 ).”
MethodThe use of animal models in diabetes research
King, A. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01911.x · Cited by 1,303
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029 · cited 1×
“Organoid chips(OoC) can be regarded as the outcome of merging biology and microtechnology, serving as micro-fluidic cell culture devices [ 72, 73].”
BackgroundDisease modeling in stem cell-derived 3D organoid systems
Dutta, D., Heo, I., & Clevers, H. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.007 · Cited by 838
Broutier, L., Andersson-Rolf, A., Hindley, C. J., Boj, S. F., Clevers, H., Koo, B.-K., & Huch, M. (2016) · Nature Protocols · doi:10.1038/nprot.2016.097 · Cited by 834 · cited 1×
“The functionality of organoids can be assessed through qPCR and single-cell or bulk cell RNA sequencing, which provide quantitation of marker gene expression, revealing cell identity and composition [ 67].”
BackgroundTumorigenicity as a clinical hurdle for pluripotent stem cell therapies
Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L., & Wu, J. C. (2013) · Nature Medicine · doi:10.1038/nm.3267 · Cited by 727
Trends in clinical success rates and therapeutic focus
Dowden, H., & Munro, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00074-z · Cited by 649 · cited 1×
“Between 2010 and 2017, clinical trials for drugs had a greater chance of failing phase І, owing to safety and efficacy [ 31].”
BackgroundAlternatives to animal testing: a review
Doke, S. K., & Dhawale, S. C. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.11.002 · Cited by 564
The Flaws and Human Harms of Animal Experimentation
AKHTAR, A. (2015) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180115000079 · Cited by 527 · cited 1×
“Physiological differences between animals and humans mean a product safe for animals may not guarantee human safety [29].”
BackgroundHuman Organoids: Tools for Understanding Biology and Treating Diseases
Schutgens, F., & Clevers, H. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032611 · Cited by 510
Hair-bearing human skin generated entirely from pluripotent stem cells
Lee, J., Rabbani, C. C., Gao, H., Steinhart, M. R., Woodruff, B. M., Pflum, Z. E., Kim, A., Heller, S., Liu, Y., Shipchandler, T. Z., et al. (2020) · Nature · doi:10.1038/s41586-020-2352-3 · Cited by 487
Modeling Alzheimer’s disease with iPSC-derived brain cells
Penney, J., Ralvenius, W. T., & Tsai, L.-H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0468-3 · Cited by 471 · cited 2×
“Neurological disorder such as Parkinson’s and Alzheimer’s have also been modeled in animals to understand their mechanisms and to determine suitable treatments [9 –11].”
BackgroundHuman heart-forming organoids recapitulate early heart and foregut development
Drakhlis, L., Biswanath, S., Farr, C.-M., Lupanow, V., Teske, J., Ritzenhoff, K., Franke, A., Manstein, F., Bolesani, E., Kempf, H., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00815-9 · Cited by 452 · cited 1×
“Additionally, methods such as immunofluorescent staining, transmission electron microscopy, and scanning electron microscopy are also utilized [ 65, 66].”
MethodThe current state of animal models in research: A review
Robinson, N. B., Krieger, K., Khan, F. M., Huffman, W., Chang, M., Naik, A., Yongle, R., Hameed, I., Krieger, K., Girardi, L. N., et al. (2019) · International Journal of Surgery · doi:10.1016/j.ijsu.2019.10.015 · Cited by 420
Historical Perspective: Models of Parkinson’s Disease
Chia, S. J., Tan, E.-K., & Chao, Y.-X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072464 · Cited by 401
FDA Modernization Act 2.0 allows for alternatives to animal testing
Han, J. J. (2023) · Artificial Organs · doi:10.1111/aor.14503 · Cited by 381 · cited 2×
“As of 2023, current regulations state that the FDA no longer deems animal tests necessary for evaluating product safety [ 4].”
BackgroundMultiorgan-on-a-Chip: A Systemic Approach To Model and Decipher Inter-Organ Communication
Picollet-D’hahan, N., Zuchowska, A., Lemeunier, I., & Le Gac, S. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.11.014 · Cited by 379
Zhao, J., Fu, Y., Yamazaki, Y., Ren, Y., Davis, M. D., Liu, C.-C., Lu, W., Wang, X., Chen, K., Cherukuri, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19264-0 · Cited by 374
Drugs, Devices, and the FDA: Part 1
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.002 · Cited by 366
Organoids — Preclinical Models of Human Disease
Li, M., & Izpisua Belmonte, J. C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806175 · Cited by 355
A brief history of animal modeling.
Ericsson, A. C., Crim, M. J., & Franklin, C. L. (2013) · Missouri medicine · Cited by 338
Research Techniques Made Simple: Animal Models of Wound Healing
Grada, A., Mervis, J., & Falanga, V. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.08.005 · Cited by 335
Experimental animal models for diabetes and its related complications—a review
Kottaisamy, C. P. D., Raj, D. S., Prasanth Kumar, V., & Sankaran, U. (2021) · Laboratory Animal Research · doi:10.1186/s42826-021-00101-4 · Cited by 263
Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells
Pleguezuelos‐Manzano, C., Puschhof, J., van den Brink, S., Geurts, V., Beumer, J., & Clevers, H. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.106 · Cited by 257
Challenges of Organoid Research
Andrews, M. G., & Kriegstein, A. R. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-090812 · Cited by 250
Takebe, T., Imai, R., & Ono, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12577 · Cited by 238
Organ-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
Ethical considerations regarding animal experimentation
Kiani, A. K., Pheby, D., HENEHAN, G. T. M., Brown, R. E., Sieving, P. A., Sýkora, P., Marks, R. S., Falsini, B., Capodicasa, N., Miertuš, S., et al. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2768 · Cited by 215
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Wang, H., Brown, P. C., Chow, E. C. Y., Ewart, L., Ferguson, S. S., Fitzpatrick, S., Freedman, B. S., Guo, G. L., Hedrich, W., Heyward, S., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13066 · Cited by 212
Human Stem Cells for Modeling Heart Disease and for Drug Discovery
Matsa, E., Burridge, P. W., & Wu, J. C. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008921 · Cited by 209
Beckwitt, C. H., Clark, A. M., Wheeler, S., Taylor, D. L., Stolz, D. B., Griffith, L., & Wells, A. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.023 · Cited by 208
Aboul-Soud, M. A. M., Alzahrani, A. J., & Mahmoud, A. (2021) · Cells · doi:10.3390/cells10092319 · Cited by 204
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.03.010 · Cited by 186
Animal testing and its alternatives—the most important omics is economics
Meigs, L. (2018) · ALTEX · doi:10.14573/altex.1807041 · Cited by 184
Ioannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175
Application of Animal Models in Cancer Research: Recent Progress and Future Prospects
Li, Z., Zheng, W., Wang, H., Cheng, Y., Fang, Y., Wu, F., Sun, G., Sun, G., Lv, C., & Hui, B. (2021) · Cancer Management and Research · doi:10.2147/cmar.s302565 · Cited by 166
Patient-derived induced pluripotent stem cells in cancer research and precision oncology
Papapetrou, E. P. (2016) · Nature Medicine · doi:10.1038/nm.4238 · Cited by 160
Deinsberger, J., Reisinger, D., & Weber, B. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-00100-4 · Cited by 158 · cited 1×
“Stem cell therapy has gained popularity throughout the medical field, and various studies are underway to gain deeper knowledge [ 5].”
BackgroundAlternatives to animal testing: current status and future perspectives
Liebsch, M., Grune, B., Seiler, A. E. M., Butzke, D., Oelgeschläger, M., Pirow, R., Adler, S., Riebeling, C., & Luch, A. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0718-x · Cited by 148
Skin-on-a-chip models: General overview and future perspectives
Risueño, I., Valencia, L., Jorcano, J. L., & Velasco, D. (2021) · APL Bioengineering · doi:10.1063/5.0046376 · Cited by 137
Multimodal spatiotemporal phenotyping of human retinal organoid development
Wahle, P., Brancati, G., Harmel, C., He, Z., Gut, G., del Castillo, J. S., Xavier da Silveira dos Santos, A., Yu, Q., Noser, P., Fleck, J. S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01747-2 · Cited by 133
Laperle, A., Sances, S., Yucer, N., Dardov, V. J., Garcia, V. J., Ho, R., Fulton, A., Jones, M. R., Roxas, K., Avalos, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0739-1 · Cited by 132
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Stoddard-Bennett, T., & Reijo Pera, R. (2019) · Cells · doi:10.3390/cells8010026 · Cited by 127
Developments and Opportunities for 3D Bioprinted Organoids
Ren, Y., Yang, X., Ma, Z., Sun, X., Zhang, Y., Li, W., Yang, H., Qiang, L., Yang, Z., Liu, Y., et al. (2024) · International Journal of Bioprinting · doi:10.18063/ijb.v7i3.364 · Cited by 126
Organ-on-a-chip technology for nanoparticle research
Kang, S., Park, S. E., & Huh, D. (2021) · Nano Convergence · doi:10.1186/s40580-021-00270-x · Cited by 108
A critical review of the assessment of eye irritation potential using the draize rabbit eye test
York, M., & Steiling, W. (1998) · Journal of Applied Toxicology · doi:10.1002/(sici)1099-1263(199807/08)18:4<233::aid-jat496>3.0.co;2-y · Cited by 103
Olgasi, C., Cucci, A., & Follenzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176215 · Cited by 100 · cited 1×
“Depending on the type or cell or method cells can be aggregated in matrix or matrixless conditions [ 75].”
BackgroundBarak, M., Fedorova, V., Pospisilova, V., Raska, J., Vochyanova, S., Sedmik, J., Hribkova, H., Klimova, H., Vanova, T., & Bohaciakova, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10254-3 · Cited by 99
Development and application of human adult stem or progenitor cell organoids
Rookmaaker, M. B., Schutgens, F., Verhaar, M. C., & Clevers, H. C. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.118 · Cited by 95
McNamee, P., Hibatallah, J., Costabel-Farkas, M., Goebel, C., Araki, D., Dufour, E., Hewitt, N. J., Jones, P., Kirst, A., Varlet, B. L., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.04.004 · Cited by 92
Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88 · cited 1×
“…that leads to scar formation and ultimately heart function failure, there are existing studies that explore iPSCs for novel therapeutic cures [ 84]. iPSC-derived progenitors such as human HCN4 + and human ESC derived ROR2 + , CD13 + , KDR + , PDGFRα + cells later generate cardiomyocytes [ 47].”
BackgroundHuman iPSC modeling of heart disease for drug development
Hnatiuk, A. P., Briganti, F., Staudt, D., & Mercola, M. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.016 · Cited by 82
Stem cells in tissues, organoids, and cancers
Wang, X. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03199-x · Cited by 76
Modeling Traumatic Brain Injury in Human Cerebral Organoids
Ramírez, S., Mukherjee, A., Sepulveda, S. E., Becerra-Calixto, A., Bravo‐Vasquez, N., Gherardelli, C., Chavez, M., & Soto, C. A. (2021) · Cells · doi:10.3390/cells10102683 · Cited by 72
iPSC technology-Powerful hand for disease modeling and therapeutic screen
Kim, C. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.100 · Cited by 70
Organ‐on‐a‐Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900754 · Cited by 70
Organoids from human tooth showing epithelial stemness phenotype and differentiation potential
Hemeryck, L., Hermans, F., Chappell, J., Kobayashi, H., Lambrechts, D., Lambrichts, I., Bronckaers, A., & Vankelecom, H. E. J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04183-8 · Cited by 65
Organ chips, organoids and the animal testing conundrum
Horejs, C. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00313-z · Cited by 64
Transplantable human thyroid organoids generated from embryonic stem cells to rescue hypothyroidism
Romitti, M., Tourneur, A., de Faria da Fonseca, B., Doumont, G., Gillotay, P., Liao, X.-H., Eski, S. E., Van Simaeys, G., Chomette, L., Lasolle, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34776-7 · Cited by 64 · cited 1×
“Thyroid follicles derived from hESCs have the potential to be used as organoids to treat hypothyroidism [ 41 ] (Table 2 ).”
BackgroundJung, S.-Y., You, H. J., Kim, M.-J., Ko, G., Lee, S., & Kang, K.-S. (2022) · iScience · doi:10.1016/j.isci.2022.105150 · Cited by 63
Gómez-Lechón, M. J., & Tolosa, L. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1756-1 · Cited by 62
Liver Organoids: Formation Strategies and Biomedical Applications
Zhu, X., Zhang, B., He, Y., & Bao, J. (2021) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-021-00357-w · Cited by 61
Parkinson’s Disease: Exploring Different Animal Model Systems
Khan, E., Hasan, I., & Haque, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109088 · Cited by 61
Animal use for science in Europe
Daneshian, M. (2015) · ALTEX · doi:10.14573/altex.1509081 · Cited by 52
Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery
Lu, Q., & Julia, T. C. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031203 · Cited by 52
Recent progress of iPSC technology in cardiac diseases
Funakoshi, S., & Yoshida, Y. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03172-3 · Cited by 52
Tradition, not science, is the basis of animal model selection in translational and applied research
Veening-Griffioen, D. H., Ferreira, G. S., Boon, W. P. C., Wied, C. C. G.-D., Schellekens, H., Moors, E. H. M., & Meer, P. J. K. V. (2020) · ALTEX · doi:10.14573/altex.2003301 · Cited by 44
Sun, Y., Wu, Q., Dai, K., You, Y., & Jiang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00675-4 · Cited by 42
Modelling Parkinson’s Disease: iPSCs towards Better Understanding of Human Pathology
Avazzadeh, S., Baena-Montes, J. M., Keighron, C. N., Sánchez, Y. F., & Quinlan, L. R. (2021) · Brain Sciences · doi:10.3390/brainsci11030373 · Cited by 40
Shi, W., Dong, P., Kuss, M. A., Gu, L., Kievit, F. M., Kim, H. J., & Duan, B. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100180 · Cited by 38
Macfarlane, M., Jones, P., Goebel, C., Dufour, E., Rowland, J., Araki, D., Costabel-Farkas, M., Hewitt, N. J., Hibatallah, J., Kirst, A., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.04.003 · Cited by 37
Wang, Y., Liang, G., Liang, S., Mund, R., Shi, Y., & Wei, H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003224 · Cited by 30
The 3R principle: advancing clinical application of human pluripotent stem cells
O’Connor, M. D. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt169 · Cited by 29
Kathuria, A., Lopez-Lengowski, K., Watmuff, B., & Karmacharya, R. (2020) · Stem Cells and Development · doi:10.1089/scd.2020.0069 · Cited by 28
Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells
Blaszkiewicz, J., & Duncan, S. A. (2022) · Genes · doi:10.3390/genes13040573 · Cited by 27
Extracellular Microenvironmental Control for Organoid Assembly
Sullivan, K. M., Ko, E. C., Kim, E. M., Ballance, W. C., Ito, J. D., Chalifoux, M., Kim, Y. J., Bashir, R., & Kong, H. (2022) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2021.0186 · Cited by 26
Alternatives to Laboratory Animals : Trends in Replacement and the Three Rs
Balls, M. (2022) · Alternatives to Laboratory Animals · doi:10.1177/02611929221082250 · Cited by 16
helen, F. J. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231158236 · Cited by 13
(2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00186-8 · Cited by 11
Kramer, N., Rosner, M., Kovačic, B., & Hengstschläger, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1763-2 · Cited by 10
How viable are alternatives to animal testing in determining the toxicities of therapeutic drugs?
Balls, M., Bailey, J., & Combes, R. D. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1694662 · Cited by 10
Aghmiuni, A. I., & Keshel, S. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823536-2.00001-8 · Cited by 3
Preclinical Animal Testing Requirements and Considerations
Centanni, J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802826-1.00002-7 · Cited by 1
Research works printed but not linked: 2
- Center for Drug Evaluation and, R., R. Center for Biologics Evaluation and, and H. International Conference on, Guidance for industry: S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals (1997). Rockville, MD: U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Center for Biologics Evaluation and Research.
- Administration, U. S. F. D. (2021). Advancing New Alternative Methodologies at FDA. Jan U.S. Food & Drug Administration: FDA website. pp. 1–34.
Cited by
Ferroptosis inhibitors: past, present and future
Zhang, L., Luo, Y., Xiang, Y., Bai, X. Y., Qiang, R. R., Zhang, X., Yang, Y. L., & Liu, X. L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407335 · Cited by 134
Artificial Intelligence Virtual Organoids (AIVOs)
Bai, L., & Su, J. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.030 · Cited by 65
Advances in 3D Organoids and Organ‐on‐a‐Chip Systems for Biomedical Research
Sakthivel, V., Dharshan, S. S., Namasivayam, S. K. R., & Arockiaraj, J. (2026) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbma.70028 · Cited by 57
Neziri, S., Köseoğlu, A. E., Köseoğlu, G. D., Özgültekin, B., & Özgentürk, N. Ö. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12487 · Cited by 47
Roy, S., Parveen, M., Bala, A., & Sur, D. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00661 · Cited by 26
Metadata
- Authors
- Park, G., Rim, Y. A., Sohn, Y., Nam, Y., & Ju, J. H.
- Affiliations
- Sungshin Women's University (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Sungkyunkwan University (KR)
- Corresponding author
- Nam, Yoojun
- Ju, Ji Hyeon
- Venue
- Stem Cell Reviews and Reports
- Published
- 2024-04-19
- Volume
- 20
- Issue
- 6
- Pages
- 1375-1386
- ISSN
- 1550-8943 (ISSN-L)
- 2629-3269
- 2629-3277
- PMC
- PMC11319430
- OpenAlex
- W4394955524
- Cited by
- 92
- References
- 90
- Citations by year
- 2026: 41 · 2025: 41 · 2024: 10
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Stem Cell Reviews and Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Korea Health Industry Development Institute (HI22C1314)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- alternatives to animal testing, organoids, organ-on-a-chip, induced pluripotent stem cells, 3D cell culture models, animal welfare, animal research ethics, regulatory considerations
- MeSH terms
- Animals, Animal Testing Alternatives, Humans, Organoids, Stem Cells, Induced Pluripotent Stem Cells, Stem Cell Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.